Addressing Treatment Gaps in Gout

Episode Summary

Executive Summary: The episode examines gout as a common but misunderstood inflammatory disease driven by excess uric acid, with most patients unable to excrete enough urate. Crystalis CEO James McKay argues current therapies often miss target levels or carry safety limits, and presents detinurad, a next-generation URAT1 inhibitor already approved in Japan and China, as a better option for moderate-to-severe gout.

Main Topics: Gout biology and disease mechanism (Priority: 5/5): McKay explains that gout results from excess uric acid, usually due to underexcretion by the kidneys, leading to crystal deposition in joints and other tissues that triggers inflammatory flares. Clinical presentation and disease burden (Priority: 5/5): The discussion covers how gout often starts with sudden painful flares, commonly in the toe or foot, but also involves silent hyperuricemia and broader systemic inflammation that can progress over years. Limitations of existing gout therapies (Priority: 5/5): Current standard treatments such as allopurinol and febuxostat often fail to bring uric acid below target, while uricase therapy is effective but burdensome and costly; McKay frames this as a major unmet need. Detinurad and the URAT1 mechanism (Priority: 5/5): Detinurad blocks the URAT1 transporter in the kidney, increasing uric acid excretion. McKay positions it as more potent and safer than prior URAT1 inhibitors, including the company’s earlier drug. Clinical development strategy and endpoints (Priority: 4/5): Crystalis is running two phase 3 trials, Ruby and Topaz, in patients failing allopurinol, using both regulatory uric-acid endpoints and patient-centered outcomes such as flare reduction and tophi resolution. Regulatory path, prior experience, and commercialization (Priority: 4/5): McKay discusses how prior approval experience with a URAT1 inhibitor and a large Asian safety database shaped the FDA strategy, with filing expected in 2028 and launch after 2029. Financing and market potential (Priority: 4/5): The company raised a large Series A and argues investor interest reflects a de-risked asset, strong team experience, and a sizable market validated by major pharma activity in gout.

Key Arguments: Most gout is not caused by diet alone; about 85% of cases stem from poor renal uric acid excretion rather than overproduction. Gout is underdiagnosed and undertreated because many patients are blamed for lifestyle factors and physicians have limited treatment options. Allopurinol is inadequate for many patients, with roughly two-thirds not reaching uric-acid targets, and febuxostat has cardiovascular safety concerns. Detinurad addresses the main pathophysiology by blocking URAT1 and increasing urinary uric acid excretion. Detinurad appears safer than prior URAT1 inhibitors because it lacks the renal toxicity issue that limited Xerampic. Japanese and Chinese clinical/post-marketing experience substantially de-risks the molecule for US and European development. The phase 3 program is designed not just to hit biomarker targets but to show meaningful patient benefit such as fewer flares, tophi resolution, and better function. Large recent financing and a competitor acquisition suggest the gout market is significant and attractive to investors and pharma.

Data Points: US patients with elevated uric acid: 50 million - McKay cites asymptomatic hyperuricemia prevalence in the US US patients expected to develop gout: 15 million - Subset of people with elevated uric acid who progress to gout Proportion of gout caused by underexcretion: 85% - Most gout patients have kidneys that cannot excrete enough uric acid Uric acid target level: <6 mg/dL - Standard regulatory and clinical target for gout control Uric acid target for tophaceous gout: <5 mg/dL - Stricter target used for patients with tophi Series A financing: $205 million - Crystalis’s financing round, described as the largest single Series A private raise in the US last year Number of investors in Series A: 13 - Investor syndicate supporting Crystalis Clinical patients exposed in Japan and China: 1,300 - Patients treated in clinical trials before the US phase 3 program Post-marketing patient exposure in Japan: 2.2 million+ - Real-world safety experience with detinurad in Japan over five years Projected post-marketing exposure by filing: 8-10 million - Estimated total Japanese post-marketing exposure by the time of US filing Ruby trial size: 500 patients - Phase 3 trial focused on gout flare outcomes Ruby treatment duration: 15 months - Follow-up period for the flare trial Topaz treatment duration: 18 months - Longer trial designed to assess tophi resolution Expected Ruby data readout: Q1 2028 - Projected timing for phase 3 flare data Expected Topaz data readout: Q2 2028 - Projected timing for phase 3 tophi data Expected regulatory filing: 2H 2028 - Planned submission timeline Expected approval: 2H 2029 - Projected approval timing after filing Known efficacy comparison: ~1000-fold more efficacious - McKay’s comparison of detinurad to the earlier URAT1 inhibitor Xerampic Boxed warning issue with prior drug: Renal toxicity at 400 mg - Prior URAT1 inhibitor had renal tox concerns that affected commercialization Competitor acquisition value: $1.5 billion - Arthrosi Therapeutics acquisition by Sobi cited as market validation Upfront cash in competitor deal: $950 million - Portion paid upfront in the Sobi-Arthrosi deal

Pivotal Quotes: "Uric acid crystals can be thought of like matches, which can sit quietly or can be ignited." — James McKay: Used to explain why crystals may remain silent for years before a gout flare occurs "About two-thirds of people who are treated with allopuranol don't actually achieve uric acid target level." — James McKay: Explaining why current first-line therapy leaves many patients uncontrolled "The thing that attracted us particularly to detinurad was that molecule was developed by a Japanese pharma company and was actually approved in Japan in 2020." — James McKay: Discussing why Crystalis chose detinurad as its lead asset

Implications: The interview suggests gout may become more aggressively and effectively treated if safer urate-lowering drugs succeed. If detinurad performs as expected, it could expand options for patients who fail allopurinol and reshape both rheumatology practice and commercial interest in gout.